Drug-coated balloon without a stent after opening long-blocked heart arteries
Tests a drug-coated balloon, with no stent, in adults with blocked heart arteries.
Plain-language title generated from the registry record
Registry title: Drug-Coated Balloon Only Strategy After Recanalization of Chronic Total Coronary Occlusions
Key facts
- Where
- São Paulo, BrazilSee the site
Where in Brazil
- InCor - Instituto do Coracao - University of Sao Paulo Heart InstituteSão Paulo, BrazilNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Sao Paulo General Hospital
- Trial code
- NCT07817719
- Record updated
- 14 September 2026
- Original description
Chronic total occlusions (CTO) of the coronary arteries are usually treated with drug-eluting stents (DES) after successful recanalization. Permanent metallic scaffolds carry recognized long-term limitations, including late malapposition, very late stent thrombosis, impairment of positive vascular remodeling, and edge restenosis after geographic miss. Drug-coated balloons (DCB) deliver an antiproliferative agent to the vessel wall without leaving a permanent implant, and may be particularly attractive in long, fibrocalcific recanalized CTO segments.Read full original descriptionShow less
NoTrace-CTO: Exclusive Drug-Coated Balloon Use After Recanalization of Chronic Total Coronary Occlusions - A Prospective, Single-Center, Single-Arm Study With Paired Quantitative Coronary Angiography and Serial Intravascular Ultrasound
Chronic total occlusions (CTO) of the coronary arteries are usually treated with drug-eluting stents (DES) after successful recanalization. Permanent metallic scaffolds carry recognized long-term limitations, including late malapposition, very late stent thrombosis, impairment of positive vascular remodeling, and edge restenosis after geographic miss. Drug-coated balloons (DCB) deliver an antiproliferative agent to the vessel wall without leaving a permanent implant, and may be particularly attractive in long, fibrocalcific recanalized CTO segments.
NoTrace-CTO is a prospective, single-center, investigator-initiated, single-arm pilot study evaluating an exclusive DCB-only strategy, with no stent implantation, after successful CTO recanalization. Thirty-eight patients are planned, to yield thirty evaluable patients with paired angiographic follow-up.
The primary endpoint is in-balloon late lumen loss at nine months, measured by quantitative coronary angiography (QCA) and tested against a pre-specified performance goal of 0.50 mm derived from a pooled contemporary second-generation DES benchmark. The proportion of lesions completing the DCB-only strategy without bailout stenting is reported descriptively alongside it. Serial intravascular ultrasound (IVUS) performed at baseline, immediately after DCB delivery and at nine months is the mechanistic centerpiece of the study, assessing vascular remodeling directly. Secondary assessments include quantitative flow ratio (QFR), Seattle Angina Questionnaire (SAQ) scores, binary restenosis, reocclusion, target lesion and target vessel revascularization, major adverse cardiovascular events (MACE), bleeding classified by the Bleeding Academic Research Consortium (BARC) criteria, and acute kidney injury defined by the Kidney Disease: Improving Global Outcomes (KDIGO) criteria.
The study is not powered for comparative clinical superiority or non-inferiority against DES; its findings are hypothesis-generating and intended to inform the design of an adequately powered multicenter trial.
Inclusion: Age 18 years or older; Chronic total coronary occlusion (CTO) of more than three months' duration, confirmed by prior angiography or lesion characteristics; Clinical indication for revascularization, defined as limiting angina and/or documented ischemia; Successful CTO recanalization, defined as restoration of Thrombolysis in Myocardial Infarction (TIMI) grade 3 antegrade flow and absence of any flow-limiting dissection; Life expectancy greater than one year; Written informed consent provided.
Exclusion: Absolute contraindication to dual antiplatelet therapy for the protocol-defined duration of 3 to 6 months; Acute coronary syndrome or cardiogenic shock at presentation; Inability to achieve adequate lesion preparation, defined as absence of flow-limiting or otherwise significant dissection and satisfactory conditions for drug delivery, confirmed by angiography and intravascular ultrasound (IVUS); Flow-limiting dissection (TIMI grade below 3) requiring stent implantation; Left main coronary artery as the CTO target vessel; Reference vessel diameter below 2.0 mm or above 4.0 mm; In-stent chronic total occlusion.